Legal status by country
Is GDF15 legal?
Written by Aaron CuhaReviewed Sep 2026
How GDF15 is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Investigational, not approved | Investigational, not licensed | Investigational, not registered | Investigational, not approved |
| Note | Native GDF15 is not a drug. The drugs that target it, ponsegromab (blocker) and MBL949 (agonist), are investigational. | None recorded | None recorded | None recorded |
US FDA status: Not FDA-approved. No GDF15 agonist or antagonist has a Drugs@FDA record as of 11 September 2026. Ponsegromab, an antibody that blocks GDF15, is in phase 2/3 for cancer cachexia; the GDF15 agonist MBL949 produced minimal weight loss in a 2025 phase 2.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.